Related Experiment Videos
Membrane cofactor protein and factor I: mutations and transplantation
David Kavanagh1, Timothy H J Goodship
1Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
Seminars in Thrombosis and Hemostasis
|April 1, 2006
Summary
Mutations in complement regulators like complement factor H (CFH) and factor I (FI) often lead to kidney failure and poor transplant outcomes in atypical hemolytic uremic syndrome (aHUS). Membrane cofactor protein (MCP) mutations show better transplant success.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Atypical hemolytic uremic syndrome (aHUS) is associated with genetic defects in complement regulatory proteins.
- Complement factor H (CFH), membrane cofactor protein (MCP), and factor I (FI) are key regulators whose mutations impact complement system function.
Purpose of the Study:
- To investigate the functional consequences of mutations in CFH, MCP, and FI in patients with aHUS.
- To establish genotype-phenotype correlations, particularly regarding end-stage renal failure and transplantation outcomes.
Main Methods:
- Analysis of functional effects of mutations on protein secretion, expression, and regulatory activity.
- Correlation of genetic mutations with clinical phenotypes, including renal failure and transplant graft survival.
Main Results:
- Mutations in CFH, MCP, and FI frequently lead to end-stage renal failure in aHUS patients.
- Transplantation outcomes are poor for CFH and FI mutation carriers (80% graft loss within 2 years) but satisfactory for MCP mutation carriers.
- Combined liver/kidney transplantation has not been successful for CFH mutation patients.
Conclusions:
- Genetic defects in complement regulators significantly influence aHUS prognosis and treatment strategies.
- MCP mutations confer a better prognosis post-transplantation due to its transmembrane nature.
- Future therapies may involve targeted complement inhibition for aHUS management.